keyword
https://read.qxmd.com/read/38251955/analysis-of-seroconversion-following-covid-19-vaccination-among-multiple-sclerosis-patients-treated-with-disease-modifying-therapies-in-poland
#21
JOURNAL ARTICLE
Aleksandra Podlecka-Piętowska, Janusz Sierdziński, Monika Nojszewska, Jakub Stawicki, Halina Bartosik-Psujek, Beata Lech, Małgorzata Popiel, Adam Perenc, Alina Kułakowska, Agata Czarnowska, Joanna Kulikowska, Katarzyna Kapica-Topczewska, Anna Jamróz-Wiśniewska, Konrad Rejdak, Jacek Zaborski, Katarzyna Kubicka-Bączyk, Natalia Niedziela, Krzysztof Wierzbicki, Monika Adamczyk-Sowa, Jacek Zwiernik, Beata Zwiernik, Marta Milewska-Jędrzejczak, Andrzej Głąbiński, Elżbieta Jasińska, Przemysław Puz, Ewa Krzystanek, Arkadiusz Stęposz, Aleksandra Karuga, Anetta Lasek-Bal, Joanna Siuda, Barbara Kściuk, Anna Walawska-Hrycek, Maja Patalong-Ogiewa, Aleksandra Kaczmarczyk, Katarzyna Siutka, Waldemar Brola, Beata Zakrzewska-Pniewska
CLINICAL RATIONALE FOR THE STUDY: The rapid spread of SARS-CoV-2 throughout the world has highlighted the importance of vaccinations to control the pandemic and to protect people at risk for severe disease courses. Disease-modifying therapies (DMT) in multiple sclerosis (MS), whether immunomodulatory or immunosuppressive, may affect the immune response. Therefore, the question arose as to whether these vaccinations would be effective. AIM OF THE STUDY: We planned a study to assess the immune response to SARS-CoV-2 vaccines by type of therapy...
January 22, 2024: Neurologia i Neurochirurgia Polska
https://read.qxmd.com/read/38235893/utilization-of-peginterferon-%C3%AE-1a-in-the-real-world-practice-for-relapsing-remitting-multiple-sclerosis
#22
JOURNAL ARTICLE
M Moccia, L Santoni, I Vaccari, G Affinito, D Caliendo, F Rubba, R Lanzillo, M Triassi, V Brescia Morra, R Palladino
OBJECTIVE: Peginterferon β-1a (PEG-IFN-β-1a) is the most recent interferon beta formulation approved for treating relapsing-remitting multiple sclerosis (RRMS). We aim to describe the real-world utilization of PEG-IFN-β-1a in RRMS and compare it with other injectable disease-modifying therapies (DMTs). PATIENTS AND METHODS: In this population-based study, we used 2015-2019 routinely collected healthcare data of the Campania region of Italy from National Healthcare System DMT prescriptions, inpatient and outpatient clinical records of hospitals in Campania, and the Federico II University MS clinical registry for a subset of patients...
January 2024: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/38181306/adverse-events-associated-with-disease-modifying-drugs-for-multiple-sclerosis-a-multiregional-population-based-study
#23
JOURNAL ARTICLE
Huah Shin Ng, Feng Zhu, Yinshan Zhao, Shenzhen Yao, Xinya Lu, Okechukwu Ekuma, Charity Evans, John D Fisk, Ruth Ann Marrie, Helen Tremlett
BACKGROUND AND OBJECTIVES: It is not possible to fully establish the safety of a disease-modifying drug (DMD) for multiple sclerosis (MS) from randomized controlled trials as only very common adverse events occurring over the short-term can be captured, and the quality of reporting has been variable. We examined the relationship between the DMDs for MS and potential adverse events in a multiregion population-based study. METHODS: We identified people with MS using linked administrative health data from 4 Canadian provinces...
February 13, 2024: Neurology
https://read.qxmd.com/read/38174776/immunomodulators-and-immunosuppressants-for-relapsing-remitting-multiple-sclerosis-a-network-meta-analysis
#24
REVIEW
Marien Gonzalez-Lorenzo, Ben Ridley, Silvia Minozzi, Cinzia Del Giovane, Guy Peryer, Thomas Piggott, Matteo Foschi, Graziella Filippini, Irene Tramacere, Elisa Baldin, Francesco Nonino
BACKGROUND: Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biological agents. Although each one of these therapies reduces relapse frequency and slows disability accumulation compared to no treatment, their relative benefit remains unclear. This is an update of a Cochrane review published in 2015. OBJECTIVES: To compare the efficacy and safety, through network meta-analysis, of interferon beta-1b, interferon beta-1a, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, pegylated interferon beta-1a, daclizumab, laquinimod, azathioprine, immunoglobulins, cladribine, cyclophosphamide, diroximel fumarate, fludarabine, interferon beta 1-a and beta 1-b, leflunomide, methotrexate, minocycline, mycophenolate mofetil, ofatumumab, ozanimod, ponesimod, rituximab, siponimod and steroids for the treatment of people with RRMS...
January 4, 2024: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/38101084/micrornas-are-dysregulated-in-peripheral-blood-mononuclear-cells-in-multiple-sclerosis-and-correlate-with-t-cell-mediators
#25
JOURNAL ARTICLE
Océane Perdaens, Vincent van Pesch
T cell mediators and microRNAs are involved in the pathogenesis of multiple sclerosis (MS), but their interaction largely remains undetermined. We investigated by RT-qPCR the dysregulation of microRNAs in peripheral blood mononuclear cells of MS patients versus healthy controls, according to radiological disease activity or treatment. Several microRNAs correlated positively/negatively with IL21/FOXP3 mRNA expression, but not with serum neurofilament light chain levels. Cytokine expression is conceivably balanced by several regulators, whereas microRNAs possibly target upstream transcription factors rather than directly cytokine mRNAs...
September 9, 2023: Journal of Neuroimmunology
https://read.qxmd.com/read/38095027/glatiramer-acetate-induces-mast-cell-degranulation-via-mrgprx2-implications-for-local-and-systemic-adverse-reactions
#26
JOURNAL ARTICLE
Shaswati Chaki, Aetas Amponnawarat, Brett Levenstein, Yvonne Hui, Carole Oskeritzian, Hydar Ali
No abstract text is available yet for this article.
December 14, 2023: Allergy
https://read.qxmd.com/read/38089033/occupational-outcomes-of-people-with-multiple-sclerosis-during-the-covid-19-pandemic-a-systematic-review-with-meta-analysis
#27
Bruno Kusznir Vitturi, Alborz Rahmani, Alfredo Montecucco, Guglielmo Dini, Paolo Durando
BACKGROUND: People with Multiple Sclerosis (PwMS) are vulnerable to unfavorable occupational outcomes and the COVID-19 pandemic brought major consequences on people's professional lives. In this view, we decided to investigate the occupational outcomes of PwMS during the COVID-19 pandemic. METHODS: We performed a systematic review with meta-analysis searching key terms in four databases. We initially included any peer-reviewed original article that enrolled adult patients with the diagnosis of MS and assessed any occupational variable during the COVID-19 pandemic...
2023: Frontiers in Public Health
https://read.qxmd.com/read/38085684/comparative-effectiveness-and-cost-effectiveness-of-natalizumab-and-fingolimod-in-rapidly-evolving-severe-relapsing-remitting-multiple-sclerosis-in-the-united-kingdom
#28
JOURNAL ARTICLE
T Spelman, W L Herring, C Acosta, R Hyde, V G Jokubaitis, E Pucci, A Lugaresi, G Laureys, E K Havrdova, D Horakova, G Izquierdo, S Eichau, S Ozakbas, R Alroughani, T Kalincik, P Duquette, M Girard, T Petersen, F Patti, T Csepany, F Granella, F Grand'Maison, D Ferraro, R Karabudak, M Jose Sa, M Trojano, V van Pesch, B Van Wijmeersch, E Cartechini, P McCombe, O Gerlach, D Spitaleri, C Rozsa, S Hodgkinson, R Bergamaschi, R Gouider, A Soysal, Castillo-Triviño, J Prevost, J Garber, K de Gans, R Ampapa, M Simo, J L Sanchez-Menoyo, G Iuliano, A Sas, A van der Walt, N John, O Gray, S Hughes, G De Luca, M Onofrj, K Buzzard, O Skibina, M Terzi, M Slee, C Solaro, Oreja-Guevara, C Ramo-Tello, Y Fragoso, V Shaygannejad, F Moore, C Rajda, E Aguera Morales, H Butzkueven
AIM: To evaluate the real-world comparative effectiveness and the cost-effectiveness, from a UK National Health Service perspective, of natalizumab versus fingolimod in patients with rapidly evolving severe relapsing-remitting multiple sclerosis (RES-RRMS). METHODS: Real-world data from the MSBase Registry were obtained for patients with RES-RRMS who were previously either naive to disease-modifying therapies or had been treated with interferon-based therapies, glatiramer acetate, dimethyl fumarate, or teriflunomide (collectively known as BRACETD)...
2024: Journal of Medical Economics
https://read.qxmd.com/read/38058171/an-update-on-combination-therapies-for-multiple-sclerosis-where-are-we-now
#29
REVIEW
Per Soelberg Sorensen, Melinda Magyari, Finn Sellebjerg
INTRODUCTION: In theory, combination of two agents, which are suboptimal when given individually, may result in a significant increase in therapeutic effect. Combination therapies have proven particularly effective against infections such as HIV, cancer, and also chronic autoimmune diseases such as rheumatoid arthritis. AREAS COVERED: The authors review the literature, searching for randomized placebo-controlled or comparative, double-blind or investigator-blinded clinical trials, not including open label clinical trials, of treatment of multiple sclerosis (MS) with combination therapy or add-on therapy, including trials of induction therapy, trials for prevention of disease activity or worsening, amelioration of adverse effects, and treatment of relapses, and trials to increase remyelination...
December 6, 2023: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38032059/adverse-effects-of-immunotherapies-for-multiple-sclerosis-a-network-meta-analysis
#30
REVIEW
Irene Tramacere, Gianni Virgili, Vittorio Perduca, Ersilia Lucenteforte, Maria Donata Benedetti, Matteo Capobussi, Greta Castellini, Serena Frau, Marien Gonzalez-Lorenzo, Robin Featherstone, Graziella Filippini
BACKGROUND: Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects mainly young adults (two to three times more frequently in women than in men) and causes significant disability after onset. Although it is accepted that immunotherapies for people with MS decrease disease activity, uncertainty regarding their relative safety remains. OBJECTIVES: To compare adverse effects of immunotherapies for people with MS or clinically isolated syndrome (CIS), and to rank these treatments according to their relative risks of adverse effects through network meta-analyses (NMAs)...
November 30, 2023: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/38011893/catalytic-antibodies-may-contribute-to-demyelination-in-myalgic-encephalomyelitis-chronic-fatigue-syndrome
#31
JOURNAL ARTICLE
Michael Anthony Jensen, Miranda Lee Dafoe, Julie Wilhelmy, Layla Cervantes, Anna N Okumu, Lucas Kipp, Mohsen Nemat-Gorgani, Ronald Wayne Davis
Here we report preliminary data demonstrating that some patients with myalgic encephalomyelitis/chronic fatiguesyndrome (ME/CFS) may have catalytic autoantibodies that cause the breakdown of myelin basic protein (MBP). We propose that these MBP-degradative antibodies are important to the pathophysiology of ME/CFS, particularly in the occurrence of white matter disease/demyelination. This is supported by magnetic resonance imagining studies that show these findings in patients with ME/CFS and could explain symptoms of nerve pain and muscle weakness...
November 27, 2023: Biochemistry
https://read.qxmd.com/read/38011449/adverse-side-effects-of-glatiramer-acetate-and-interferon-beta-1a-in-patients-with-multiple-sclerosis-a-systematic-review-of-case-reports
#32
JOURNAL ARTICLE
Mohsen Rastkar, Mahsa Ghajarzadeh, Mohammad Ali Sahraian
Background: Glatiramer acetate (GA) and Interferon (IFN) beta-1a are used as first-line disease-modifying treatments for multiple sclerosis (MS). In this systematic review, we summarized case reports and case series of adverse side effects of GA and IFN beta-1a in MS patients. Methods: Without any restrictions, PubMed, Scopus, Web of Sciences, and Embase databases, and gray literature were systemically searched until June 2022. Articles were screened and data were extracted based on a predefined table by two independent reviewers...
April 4, 2023: Current journal of neurology
https://read.qxmd.com/read/38004525/exploiting-pharma-4-0-technologies-in-the-non-biological-complex-drugs-manufacturing-innovations-and-implications
#33
REVIEW
Vera Malheiro, Joana Duarte, Francisco Veiga, Filipa Mascarenhas-Melo
The pharmaceutical industry has entered an era of transformation with the emergence of Pharma 4.0, which leverages cutting-edge technologies in manufacturing processes. These hold tremendous potential for enhancing the overall efficiency, safety, and quality of non-biological complex drugs (NBCDs), a category of pharmaceutical products that pose unique challenges due to their intricate composition and complex manufacturing requirements. This review attempts to provide insight into the application of select Pharma 4...
October 28, 2023: Pharmaceutics
https://read.qxmd.com/read/38004432/disease-modifying-therapies-dmts-in-pregnant-and-lactating-women-with-multiple-sclerosis-analysis-of-real-world-data-from-eudravigilance-database
#34
JOURNAL ARTICLE
Liberata Sportiello, Raffaella Di Napoli, Nunzia Balzano, Annamaria Mascolo, Rosanna Ruggiero, Luigi Di Costanzo, Davida Monaco, Giorgia Teresa Maniscalco, Annalisa Capuano
(1) Background: The purpose of study was to compare the safety profile of glatiramer with natalizumab, alemtuzumab and ocrelizumab in pregnant and lactating women affected by multiple sclerosis (MS). (2) Methods: Individual case safety reports (ICSRs) were retrieved from the European spontaneous reporting system database (EudraVigilance). The reporting odds ratios (RORs) were computed to compare the reporting probability of events between natalizumab, alemtuzumab and ocrelizumab vs. glatiramer. (3) Results: A total of 1236 ICSRs reporting at least one DMT as a suspected drug were selected...
November 6, 2023: Pharmaceuticals
https://read.qxmd.com/read/37981250/novel-liposomal-glatiramer-acetate-preparation-and-immunomodulatory-evaluation-in-murine-model-of-multiple-sclerosis
#35
JOURNAL ARTICLE
Niloufar Rahiman, Parvin Zamani, Leila Arabi, Seyedeh Hoda Alavizadeh, Aminreza Nikpoor, Mohammad Mashreghi, Ali Badiee, Mahmoud Reza Jaafari
The frequent administration rate required for Glatiramer acetate (GA), a first-line therapy for Multiple sclerosis (MS), poses patient compliance issues. Only a small portion of the subcutaneously administered GA is available for phagocytosis by macrophages, as most of it is hydrolyzed at its administration site or excreted renally. To unravel these hurdles, we have prepared liposomal formulations of GA through thin film-hydration method plus extrusion. The clinical and histopathological efficacy of GA-loaded liposomes were assessed in prophylactic and therapeutic manners on murine model of MS (experimental autoimmune encephalomyelitis (EAE))...
November 17, 2023: International Journal of Pharmaceutics
https://read.qxmd.com/read/37909320/satisfaction-and-practicality-of-a-prefilled-glatiramer-acetate-pen-in-relapsing-remitting-multiple-sclerosis-patients
#36
MULTICENTER STUDY
Herbert Schreiber, Joachim Hipp, Fabian Roßnagel, Christiane Moritz
Aim: Evaluation of practicality and patient satisfaction of a glatiramer acetate (GA) prefilled pen in patients with relapsing-remitting multiple sclerosis (RRMS). Patients & methods: A cross-sectional, multicenter, observational study evaluating patients' experiences with the GA-pen 3 months after its first use by means of self-reporting questionnaires. Primary end point was the proportion of patients who were satisfied with the pen. Results: 80 patients participated in the study. The majority (83...
October 2023: Neurodegenerative Disease Management
https://read.qxmd.com/read/37893133/micrornas-associated-with-disability-progression-and-clinical-activity-in-multiple-sclerosis-patients-treated-with-glatiramer-acetate
#37
JOURNAL ARTICLE
Ignacio Casanova, María I Domínguez-Mozo, Laura De Torres, Yolanda Aladro-Benito, Ángel García-Martínez, Patricia Gómez, Sara Abellán, Esther De Antonio, Roberto Álvarez-Lafuente
MicroRNAs (miRNAs) are promising biomarkers in multiple sclerosis (MS). This study aims to investigate the association between a preselected list of miRNAs in serum with therapeutic response to Glatiramer Acetate (GA) and with the clinical evolution of a cohort of relapsing-remitting MS (RRMS) patients. We conducted a longitudinal study for 5 years, with cut-off points at 2 and 5 years, including 26 RRMS patients treated with GA for at least 6 months. A total of 6 miRNAs from a previous study (miR-9.5p, miR-126...
October 12, 2023: Biomedicines
https://read.qxmd.com/read/37845751/the-effect-of-glatiramer-acetate-ifn%C3%AE-1a-fingolimod-and-dimethyl-fumarate-on-the-expression-of-t-bet-ifn-%C3%AE-and-meg3-in-pbmc-of-rrms-patients
#38
JOURNAL ARTICLE
Rozhin Dabbaghi, Reza Safaralizadeh, Shima Rahmani, Nesa Barpour, Mohammadali Hosseinpourfeizi, Ali Rajabi, Behzad Baradaran
OBJECTIVE: Multiple sclerosis (MS) is a progressing neurodegenerative disease marked by chronic central nervous system inflammation and degeneration.This study investigates gene expression profiles of T-box transcription factor TBX21 (T-bet), interferon-gamma (IFN-γ), and long non-coding RNA MEG3 in peripheral blood mononuclear cells (PBMCs) from treatment-naïve Relapsing-Remitting Multiple Sclerosis patients (RRMS), healthy controls, and RRMS patients on different Disease Modifying Therapies (DMTs)...
October 16, 2023: BMC Research Notes
https://read.qxmd.com/read/37813594/multiple-sclerosis-disease-modifying-therapies-and-infections
#39
JOURNAL ARTICLE
Annette M Langer-Gould, Jessica B Smith, Edlin G Gonzales, Fredrik Piehl, Bonnie H Li
BACKGROUND AND OBJECTIVES: The use of highly effective multiple sclerosis (MS) disease-modifying therapies (DMTs) is rapidly increasing. Yet, little is known about their real-world risks of infections. The goals of this study were to assess the comparative risk of outpatient and serious infections across DMTs in a large, diverse, U.S. cohort and determine whether such risks are attributable to DMTs, having MS, or other factors. METHODS: We conducted a retrospective cohort study of Kaiser Permanente Southern California members from 2008 through 2020 with MS and non-MS controls matched on age, sex, race, and ethnicity...
November 2023: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/37781240/clinical-predictors-of-neda-3-one-year-after-diagnosis-of-pediatric-multiple-sclerosis-an-exploratory-single-center-study
#40
JOURNAL ARTICLE
Filipe Palavra, Diogo Silva, Catarina Fernandes, Ricardo Faustino, Mónica Vasconcelos, Cristina Pereira, Carmen Costa, Joana Afonso Ribeiro, Joana Amaral, Conceição Robalo
INTRODUCTION: Multiple sclerosis (MS) is an inflammatory and demyelinating disorder of central nervous system that can be diagnosed in pediatric age (<18 years) in 3-5% of the cases. This early onset is associated with higher relapse rates and earlier progression to neurological disability. By using NEDA-3 (No Evidence of Disease Activity-3) criteria, we aimed to identify clinical predictors associated with absence of disease activity and control of disease progression 12 months after the diagnosis, in a cohort of pediatric-onset MS (POMS) patients regularly followed-up in our center...
2023: Frontiers in Neuroscience
keyword
keyword
98584
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.